NO20050204L - Kombinasjoner av legemidler for behandling av neoplasmer - Google Patents

Kombinasjoner av legemidler for behandling av neoplasmer

Info

Publication number
NO20050204L
NO20050204L NO20050204A NO20050204A NO20050204L NO 20050204 L NO20050204 L NO 20050204L NO 20050204 A NO20050204 A NO 20050204A NO 20050204 A NO20050204 A NO 20050204A NO 20050204 L NO20050204 L NO 20050204L
Authority
NO
Norway
Prior art keywords
neoplasms
drugs
combinations
treatment
patient
Prior art date
Application number
NO20050204A
Other languages
English (en)
Inventor
Curtis Keith
Michael A Foley
Brent R Stockwell
Alexis Borisy
Debra A Gaw
James M Nichols
Margaret S Lee
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of NO20050204L publication Critical patent/NO20050204L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

Det beskrives en fremgangsmåte for behandling av en pasient som har en cancer eller annen neoplasme, ved å administrere pasienten to forbindelser samtidig eller innen 14 dagers mellomrom, i mengder som er tilstrekkelige til å behandle pasienten.
NO20050204A 2002-07-11 2005-01-13 Kombinasjoner av legemidler for behandling av neoplasmer NO20050204L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39523302P 2002-07-11 2002-07-11
PCT/US2003/021803 WO2004006842A2 (en) 2002-07-11 2003-07-11 Combinations of drugs for the treatment of neoplasms

Publications (1)

Publication Number Publication Date
NO20050204L true NO20050204L (no) 2005-04-08

Family

ID=30115841

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050204A NO20050204L (no) 2002-07-11 2005-01-13 Kombinasjoner av legemidler for behandling av neoplasmer

Country Status (15)

Country Link
US (2) US20040116407A1 (no)
EP (1) EP1545544A2 (no)
JP (1) JP2005536509A (no)
CN (1) CN1681511A (no)
AU (1) AU2003256511A1 (no)
BR (1) BR0312597A (no)
CA (1) CA2492059A1 (no)
HR (1) HRP20050115A2 (no)
IL (1) IL166217A0 (no)
IS (1) IS7691A (no)
MX (1) MXPA05000485A (no)
NO (1) NO20050204L (no)
RU (1) RU2005103610A (no)
WO (1) WO2004006842A2 (no)
ZA (1) ZA200500618B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
FR2842423B1 (fr) * 2002-07-18 2005-07-08 Centre Nat Rech Scient Composes a activite anti-parasitaire et medicaments les renfermant
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
CA2517802A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein tyrosine phosphatase-prl-1 a a marker and therapeutic target for pancreatic cancer
US20050054708A1 (en) * 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
US20050080075A1 (en) * 2003-08-25 2005-04-14 Nichols M. James Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
WO2005023179A2 (en) * 2003-08-29 2005-03-17 Aton Pharma, Inc. Combination methods of treating cancer
WO2005027842A2 (en) * 2003-09-18 2005-03-31 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
WO2005051296A2 (en) * 2003-11-24 2005-06-09 University Of North Carolina At Chapel Hill Fused ring dicationic anti-protozoan agents and their prodrugs
WO2005070126A2 (en) * 2004-01-08 2005-08-04 The Regents Of The University Of Colorado Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
AU2005316652B2 (en) * 2004-12-15 2009-07-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combinations of therapeutic agents for treating cancer
TW200719903A (en) * 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms
CA2611735A1 (en) * 2005-04-28 2006-11-02 The Regents Of The University Of Colorado Therapeutic bifunctional compounds
CA2611738A1 (en) * 2005-05-02 2006-11-09 The Regents Of The University Of Colorado Systems and methods for treating human inflammatory and proliferative diseases, with a combination of compounds, or a bifunctional compound,that provides fatty acid metabolism andglycolysis inhibition
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
BRPI0520686A2 (pt) * 2005-11-16 2009-05-19 Univ Mexico Nacional Autonoma uso de agentes modificantes de transcriptoma associado a quimioterapia ou radioterapia contra o cáncer
WO2008016890A1 (en) * 2006-07-31 2008-02-07 Abbott Laboratories Antitumorigenic drug combination
EP2192904B1 (en) * 2007-08-27 2016-08-17 Auxagen, Inc. METHODS FOR INHIBITING TGF-beta
WO2009105230A2 (en) * 2008-02-21 2009-08-27 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
US9073985B2 (en) 2008-07-14 2015-07-07 The Regents Of The University Of Colorado, A Body Corporate Methods and products for treating proliferative diseases
US8487006B2 (en) * 2008-09-16 2013-07-16 Auxagen, Inc. Method of enhancing TGF-β signalling
EP2617414A3 (en) * 2008-10-01 2013-11-06 Novartis AG Smoothened antagonism for the treatment of hedgehog pathway-related disorders
NZ596365A (en) * 2009-05-01 2013-11-29 Oncozyme Pharma Inc Pentamidine combinations for treating cancer
ITRM20090578A1 (it) * 2009-11-10 2011-05-11 Noi Per Voi Onlus Nuove composizioni per il trattamento di leucemie chemioresistenti e/o di leucemie potenzialmente chemioresistenti.
US8809299B2 (en) * 2012-03-28 2014-08-19 Mcmaster University Combination therapy for the treatment of cancer
CN105030785B (zh) * 2015-06-30 2017-11-10 上海交通大学 Promethazine在制备抗肝癌和/或结肠癌和/或肺癌产品中的应用
EP3789029B1 (en) * 2018-05-04 2024-05-08 Korea Institute of Radiological & Medical Sciences Radiation sensitivity enhancing composition containing aripiprazole as active ingredient
CN113264925A (zh) * 2020-02-14 2021-08-17 上海美悦生物科技发展有限公司 一种杂环化合物及其制备方法和用途
CN113304155B (zh) * 2021-05-24 2023-03-24 四川大学华西医院 一种抗肿瘤的药物组合物及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2645640A (en) * 1953-07-14 Phenthiazine derivatives
DE3827974A1 (de) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders

Also Published As

Publication number Publication date
WO2004006842A3 (en) 2004-05-27
HRP20050115A2 (en) 2005-10-31
JP2005536509A (ja) 2005-12-02
MXPA05000485A (es) 2005-04-19
CN1681511A (zh) 2005-10-12
WO2004006842A2 (en) 2004-01-22
IL166217A0 (en) 2006-01-15
IS7691A (is) 2005-02-09
ZA200500618B (en) 2006-08-30
BR0312597A (pt) 2005-05-10
US20070099905A1 (en) 2007-05-03
CA2492059A1 (en) 2004-01-22
EP1545544A2 (en) 2005-06-29
RU2005103610A (ru) 2005-08-27
AU2003256511A1 (en) 2004-02-02
US20040116407A1 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
NO20050204L (no) Kombinasjoner av legemidler for behandling av neoplasmer
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
BR0109703A (pt) Derivados de piperazina
HK1086186A1 (en) Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain
BR0317717A (pt) Composto, composição farmacêutica, uso de um composto, método para tratar um humano sofrendo de uma doença, e, processo para a preparação de um composto
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0309890A (pt) Composição farmacêutica contendo plasma sanguìneo, ou soro sanguìneo utilizada no tratamento de lesões, bem como seu método e processo de aplicação
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
NO20054361L (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BRPI0518000A (pt) tetrahidroisoquinolinas aril- e heteroaril- substituìdas e uso das mesmas para bloquear a reabsorção de norepinefrina, dopamina e serotonina
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
NO20061417L (no) Syreinneholdende oxaliplatinformuleringer
DE502004008819D1 (de) Medikament zur wachstumsinhibierung von tumoren
NO20045370L (no) Anvendelse av docetaxel/doxorubicin/cyklofosfamid i adjuvansterapi av bryst og ovariekreft
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
WO2004006849A3 (en) Combinations of drugs for the treatment of neoplasms
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application